From new systemic therapy combinations in platinum-resistant ovarian cancer (PROC) to emerging targeted options for low-grade serous disease, a wave of clinical progress is expanding treatment possibilities, according to Brian Slomovitz, MD.
From new systemic therapy combinations in platinum-resistant ovarian cancer (PROC) to emerging targeted options for low-grade serous disease, a wave of clinical progress is expanding treatment possibilities, according to Brian Slomovitz, MD.